PEGBIO CO-B (02565.HK): Enters Joint R&D Collaboration with SN BioScience for Long-Acting Metabolic Disease Peptides

NewTimeSpace News: On 2 September 2026, PegBio Co., Ltd. (stock code: 02565) announced that it has entered into a material transfer agreement with SN BioScience, Inc., a Korean biotech company, under which SN BioScience will apply its self-developed serinol nucleic acid (SNA) long-acting drug delivery platform to three of the Group's self-developed innovative metabolic disease peptide candidates, including APGP6, with joint research to be conducted on formulation and long-acting delivery of the candidates.

According to the announcement, the collaboration covers three drug candidates at once rather than a single product, allowing parallel validation of the technical fit between the SNA platform and the Group's next-generation peptide assets, and exploring the potential to extend duration of action, optimise dosing regimens and improve overall product profiles.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.